Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Tunica Albuginea who wrote (869)	11/23/1997 9:46:00 PM
From: Anaxagoras	Read Replies (1) \| Respond to of 7041

Big Tuna, once again, your haphazard way with truth has landed you in a blatant mistake. However, as usual, when caught in an easily verifiable mistake, you will simply say "oops, gee whiz, ahhhh", and wave your hands about. How can anyone take your comments seriously when you claim the half-life of phentolamine when taken orally is five minutes? You are wrong; not even close. It's a shame you didn't take the time to listen to the ZONA conference call (but then again, you would prefer to waste your time spewing senseless drivel over the internet in a vain attempt to intimidate others with your anonymous credentials). On several occassions it was mentioned that the half-life is approximately 19 minutes, i.e. about every 19 minutes the concentration of phentolamine is cut in half in the blood. And this is of primary importance, for if you use a standard tablet formulation that disintegrates in 30 minutes or less you're trickling this drug into the blood and it's getting metabolized and cleared before it can get to any appreciable formulation. Now this is precisely the interesting thing about Zonagen. In their second patent (which they believe they will be issuing shortly) they teach how to deliver this drug in a high concentration so that you can achieve effective blood levels and those blood levels overcome the half-life problem. This also is a patentable event that both the company and their counsel think is strongly defensible. But here's the plain and simple point- if you can't even get the simplest of facts straight, if you insist upon playing fast and free with the easy points, why should anyone listen to your other tedious anecdotes of a rheumy-eyed physician? Anaxagoras